Search research articles
Contact Us
Filters
Showing results (81-90 of 103) with videos related to
Page
of 11
Sort By:
Leukemia & Lymphoma
|
July 10, 2026
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
Joshua Richter, Hans C Lee, Sundar Jagannath, et al.
Blood Advances
|
August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 1, 2025
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Hans C Lee, Naresh Bumma, Joshua Richter, et al.
Blood Advances
|
September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
Urvi A Shah, Erin Moshier, Andriy Derkach, et al.
JCI Insight
|
May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma
Sridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood Cancer Discovery
|
September 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
Santiago Thibaud, Ryan L Subaran, Scott Newman, et al.
Future Oncology (London, England)
|
July 14, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma
Carlyn Rose Tan, Lucio Gordan, Joshua Richter, et al.
Blood
|
November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Neoplasia
|
June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Rudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Leukemia & Lymphoma
|
August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
Oliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 103) with videos related to
Sort By:
Page
of 11
Leukemia & Lymphoma
|
July 10, 2026
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
Joshua Richter, Hans C Lee, Sundar Jagannath, et al.
Blood Advances
|
August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 1, 2025
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Hans C Lee, Naresh Bumma, Joshua Richter, et al.
Blood Advances
|
September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
Urvi A Shah, Erin Moshier, Andriy Derkach, et al.
JCI Insight
|
May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma
Sridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood Cancer Discovery
|
September 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
Santiago Thibaud, Ryan L Subaran, Scott Newman, et al.
Future Oncology (London, England)
|
July 14, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma
Carlyn Rose Tan, Lucio Gordan, Joshua Richter, et al.
Blood
|
November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Neoplasia
|
June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Rudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Leukemia & Lymphoma
|
August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
Oliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Page
of 11